Clinical trials referenced in this document:
Funding for this research was provided by:
Consejo Nacional de Ciencia y Tecnología (127088, 71260)
National Institutes of Health (HHSN261200800001E, HHSN261201500003I)
Received: 26 February 2020
Accepted: 2 August 2021
First Online: 28 August 2021
: The study protocol was approved by an Institution Review Board in all participating institutions in Mexico. Signed informed consent was obtained from all subjects. Participation of minors (< 18 year old) was consented by their legal guardians and their verbal (< 8 year old) or written (8–17 year old) assent was requested. If subjects were not able to sign the consent form because of the severity of the disease, a legal representative was asked to sign the consent form. The study was reviewed and approved by the Comité de Ética en Investigación (Comittee on Ethics in Research) and the Comité de Investigación (Research Comittee) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INF-2636-18-19-1) for implementation at the General Hospital of Tapachula City, Hospital Regional de Alta Especialidad Ciudad Salud, and Clínica Dr. Roberto Nettel Flores, ISSSTE. The protocol was reviewed and approved by the Comité de Ética en Investigación (Comittee on Ethics in Research) and the Comité de Investigación (Research Comittee) of the Instituto Mexicano del Seguro Social (Ref 09-B5-61-2800/201600/2378).
: Not applicable.
: Pablo-Belaunzarán Zamudio is an Associate Editor of BMC Infectious Diseases. The other authors declare that they have no competing interests.